Literature DB >> 2838854

Effects of caloric restriction and exercise on B-endorphin, ACTH and cortisol circulating levels in obesity.

D Scavo1, C Barletta, R Buzzetti, D Vagiri.   

Abstract

B-Endorphin (B-Ep), ACTH and cortisol circulating levels, before and after a two months therapy with a hypocaloric diet and an increase in physical exercise, were measured by RIA in 17 obese female subjects. After therapy, the body weight excess fell from 56.6 +/- 22.2% to 38.6 +/- 22.1% (p less than 0.01). Plasma levels of B-Ep decreased from 18.3 +/- 12.5 fmol/ml to 6.4 +/- 3.5 fmol/ml (p less than 0.01); those of ACTH from 46.8 +/- 22.8 pg/ml to 31.2 +/- 11.6 pg/ml (p less than 0.01); and those of cortisol from 15.9 +/- 4.6 micrograms% to 10.3 +/- 2.5 micrograms% (p less than 0.01). The reduction of the elevated plasma B-Ep levels found in obese subjects is related principally to the diet therapy. Thus, as shown in experimental animals, excessive feeding results in an increased hypothalamic-pituitary secretion of B-Ep.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2838854     DOI: 10.1016/0031-9384(88)90261-2

Source DB:  PubMed          Journal:  Physiol Behav        ISSN: 0031-9384


  3 in total

1.  The effect of the weight reduction on the salivary cortisol levels of judo players.

Authors:  M Toda; K Morimoto; S Fukuda; T Umeda; S Nakaji; K Sugawara
Journal:  Environ Health Prev Med       Date:  2001-07       Impact factor: 3.674

2.  Opioid-receptor antagonism increases pain and decreases pleasure in obese and non-obese individuals.

Authors:  Rebecca C Price; Nicolas V Christou; Steven B Backman; Laura Stone; Petra Schweinhardt
Journal:  Psychopharmacology (Berl)       Date:  2016-09-22       Impact factor: 4.530

3.  Low-level prenatal and postnatal blood lead exposure and adrenocortical responses to acute stress in children.

Authors:  Brooks B Gump; Paul Stewart; Jacki Reihman; Ed Lonky; Tom Darvill; Patrick J Parsons; Douglas A Granger
Journal:  Environ Health Perspect       Date:  2008-02       Impact factor: 9.031

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.